comparemela.com
Home
Live Updates
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data : comparemela.com
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure Continues to be... | December 6, 2021
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Philadelphia ,
Pennsylvania ,
United States ,
Canada ,
Kaitlin Gallagher ,
Franke Weise ,
Bryan Stuart ,
Stephanie Ascher ,
Naomi Aoki ,
Christi Waarich ,
Gerd Blobel ,
Stern Investor Relations Inc ,
Drug Administration ,
Nasdaq ,
Embryonic Ectoderm Development ,
Replay International Number ,
Exchange Commission ,
International Number ,
Fulcrum Therapeutics Inc ,
Corporate Communications ,
Berry Company Public Relations ,
Clinical Development ,
Globenewswire Inc ,
Pediatric Hematology ,
Achieved Maximal ,
Higher Doses ,
Fold Induction ,
Hbf Master Regulators ,
Development Plans ,
Investigational New Drug ,
Investor Relations ,
Dial In Number ,
International Dial In Number ,
Ectoderm Development ,
Private Securities Litigation Reform Act ,
Vice President ,
Fulcrum Therapeutics ,
Nc Stock Exchange ,
News ,
Information ,
Press Release ,
Chieved ,
Sean ,
Bg ,
Rna ,
Nduction ,
It ,
40mg ,
End ,
After ,
4 ,
Ways ,
F ,
Urther ,
Supporting ,
Potential ,
O ,
Rovide ,
Unctional ,
Cure ,
Ontinues ,
O Fulc Us3596161097 ,
comparemela.com © 2020. All Rights Reserved.